Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

LIQUID BIOPSIES

Enhanced cancer detection from cell-free DNA

Nature Biotechnology volume 40, pages 473–474 (2022)Cite this article

Subjects

A new assay for cell-free DNA fragmentation improves prediction of gene expression in liquid biopsies.

Previous studies of cfDNA have led to noninvasive methods for prenatal testing3, cancer liquid biopsy4 and transplantation monitoring5. Early work in the field focused on detection of genetic variations, such as single-nucleotide mutations. In patients with cancer, because the vast majority of cfDNA fragments is not mutated, typically cancers at advanced stages are more readily detected. Studies have indicated that the fragmentation patterns of cfDNA — including fragment sizes6,7, fragment ends8, jagged ends9 and nucleosome footprints10,11 — might carry information related to the tissues of origin. These studies suggest that cfDNA fragmentation patterns reflect underlying chromatin structures and gene expression. However, these previous studies were not specifically designed for resolving RNA expression levels of individual genes using cfDNA fragmentation patterns.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Fig. 1: Analysis of the diversity of fragment sizes.

References

  1. Esfahani, M. S. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-022-01222-4 (2022).

  2. Lo, Y. M. D., Han, D. S. C., Jiang, P. & Chiu, R. W. K. Science 372, eaaw3616 (2021).

    CAS  Article  PubMed  Google Scholar 

  3. Lo, Y. M. et al. Lancet 350, 485–487 (1997).

    CAS  Article  PubMed  Google Scholar 

  4. Chen, X. Q. et al. Nat. Med. 2, 1033–1035 (1996).

    CAS  Article  PubMed  Google Scholar 

  5. Lo, Y. M. et al. Lancet 351, 1329–1330 (1998).

    CAS  Article  PubMed  Google Scholar 

  6. Chan, K. C. A. et al. Clin. Chem. 50, 88–92 (2004).

    CAS  Article  PubMed  Google Scholar 

  7. Zheng, Y. W. L. et al. Clin. Chem. 58, 549–558 (2012).

    CAS  Article  PubMed  Google Scholar 

  8. Jiang, P. et al. Cancer Discov. 10, 664–673 (2020).

    CAS  PubMed  Google Scholar 

  9. Jiang, P. et al. Genome Res. 30, 1144–1153 (2020).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. Sun, K. et al. Genome Res. 29, 418–427 (2019).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. Snyder, M. W., Kircher, M., Hill, A. J., Daza, R. M. & Shendure, J. Cell 164, 57–68 (2016).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. Liu, M. C., Oxnard, G. R., Klein, E. A., Swanton, C. & Seiden, M. V. Ann. Oncol. 31, 745–759 (2020).

    CAS  Article  PubMed  Google Scholar 

  13. Ulz, P. et al. Nat. Genet. 48, 1273–1278 (2016).

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Novostics, Hong Kong Science Park, Hong Kong Special Administrative Region, China

    Peiyong Jiang & Y. M. Dennis Lo

  2. Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China

    Peiyong Jiang & Y. M. Dennis Lo

  3. State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China

    Y. M. Dennis Lo

Authors
  1. Peiyong Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y. M. Dennis Lo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y. M. Dennis Lo.

Ethics declarations

Competing interests

Y.M.D.L. holds equity in DRA, Take2 and Grail/Illumina. Y.M.D.L. is a scientific cofounder of Grail. P.J. holds equity in DRA and Grail/Illumina. P.J. is a consultant to Take2. P.J. is a Director of KingMed Future. Patent royalties are received from Grail, Illumina, Sequenom, DRA, Take2 Health and Xcelom.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jiang, P., Lo, Y.M.D. Enhanced cancer detection from cell-free DNA. Nat Biotechnol 40, 473–474 (2022). https://doi.org/10.1038/s41587-021-01207-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-021-01207-9

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing